Injectables
The latest in injectables for medical-aesthetics practice owners.
Injectables
AbbVie Launches Boey, Rapid-Onset Toxin, in Europe
New neuromodulator formulation targets faster onset; competitive pressure on Botox pricing intensifies.
Injectables
JUVÉDERM Day Returns August 19—Promo Details
AbbVie relaunches its annual promotional event with BOGO gift cards and discounts.
Injectables
SKINVIVE Neck-Line Indication Expands Filler Market
FDA-approved JUVÉDERM product now marketed for neck lines, opening new treatment area.
Injectables
Galderma Launches Sculptra in India—Regenerative Expansion
Poly-L-lactic acid biostimulator enters India market as Galderma builds APAC footprint.
Injectables
AbbVie Q2 2026: Aesthetics Growth Outpaces Pharma
Botox and Juvéderm momentum continues; pricing and mix drive segment expansion.
Injectables
Evolus Q2 2023: Revenue Breakdown Signals Jeuveau Stabilization
Toxin maker's earnings reveal where Jeuveau stands against Botox and Dysport in competitive market.
Injectables
Daewoong's Nabota Reaches 1 Trillion Won in Cumulative Sales, Signals Korean Toxin Momentum
South Korean botulinum toxin A crosses major revenue threshold, validating regional demand and manufacturing scale.
Injectables
AbbVie Launches Boey, Rapid-Onset Botulinum Toxin, With EU Approval
New formulation claims faster onset than Botox; FDA pathway in U.S. unclear.
Injectables
Xeomin Enters Neurotoxin Resistance Conversation as Clinical Data Accumulates
Revance's incobotulinumtoxinA gains traction in discussions around antibody formation and repeat-patient efficacy.
Injectables
Hugel Builds US Direct Sales Force for Letybo, Launches K-TOX Campaign
South Korean toxin maker escalates stateside presence with dedicated field team and branded marketing push.
Injectables
Allergan Aesthetics Wins EU Approval for Boey — First Rapid-Onset, Short-Duration Neuromodulator
AbbVie's Allergan Aesthetics gains European clearance for trenibotulinumtoxinE, a faster-acting botulinum toxin with shorter duration than traditional formulations.
Injectables
AbbVie's Boey Wins EU Approval for Frown Lines — First Rapid-Onset Botox Alternative
Allergan Aesthetics' trenibotulinumtoxinE gains European clearance as a faster-acting, shorter-duration neuromodulator.
Injectables
Daewoong Pharma's Nabota Surpasses 1 Trillion Won in Sales — South Korean Toxin Accelerates Global Expansion
Nabota's domestic milestone signals momentum in international markets as a third-party botulinum toxin alternative.
Injectables
Allergan Aesthetics Wins EU Approval for Boey — First Rapid-Onset, Short-Duration Neuromodulator
The rapid-acting toxin enters Europe; implications for glabellar-only positioning and unit economics remain to be tested.
Injectables
Allergan Aesthetics Wins EU Approval for Boey — First Rapid-Onset, Short-Duration Neurotoxin Reshapes Toxin Economics
Boey (trenibotulinumtoxinE) becomes the first rapid-onset, short-duration neuromodulator approved in Europe, fragmenting the toxin market.
Injectables
Evolus Expands Jeuveau Rewards Program — Aggressive Pricing War Targets Medspa Market Share
Evolus's enhanced loyalty program and aggressive rebate positioning challenge AbbVie's Botox dominance in the medspa channel.
Injectables
Evolus Aggressively Markets Jeuveau Through Rewards Program — Neuromodulator Price Wars Intensify
Evolus' expanded Evolus Rewards loyalty program targets medspa market share as Jeuveau pricing pressure mounts.
Injectables
Daewoong Pharma's Nabota Exceeds 1 Trillion Won in Sales, Accelerates Global Push
South Korean neuromodulator maker scales international distribution as price competition intensifies.
Injectables
Evolus Ramps Jeuveau Marketing to Medspas via Evolus Rewards Program
Neuromodulator maker escalates direct-to-medspa strategy as price competition intensifies.
Injectables
Evolus Aggressively Markets Jeuveau to Medspas via Rewards Program — Price War Signals Intensify
Newtox's maker doubles down on loyalty incentives as neuromodulator competition heats up.
Injectables
AbbVie Allergan Files Material Event — Botox/Juvéderm Pricing or Rebate Shift Likely Imminent
The bellwether injectable maker signals changes to Allē loyalty program or product pricing.
Injectables
Evolus Secures Exclusive U.S. License for Profhilo — 15-Year Term, No Upfront Fee
Injectable biotech adds hyaluronic acid biostimulator to portfolio; no upfront payment signals confidence in market adoption.
Injectables
Evolus Secures Exclusive U.S. Profhilo License From IBSA — Skin Quality Injectable Now in Play
Evolus expands beyond neuromodulator competition with a 15-year exclusive deal for the hydration-focused biostimulator, no upfront fees.
Injectables
Evolus Secures Exclusive U.S. Profhilo License From IBSA — A Skin-Quality Play to Challenge Juvéderm
No upfront payment; 15-year term positions Evolus in the hydrating-filler segment.
Injectables
Evolus Secures Exclusive U.S. Rights to Profhilo From IBSA — 15-Year Term, No Upfront Fee
Evolus expands injectable portfolio into skin quality with IBSA's hyaluronic acid biostimulator.
Injectables
Allergan Wins FDA Nod for SKINVIVE by JUVÉDERM for Neck — New Indication, Familiar Economics
The FDA cleared SKINVIVE by JUVÉDERM for neck appearance improvement, expanding the HA filler's approved indications.
Injectables
Allergan Aesthetics Wins FDA Approval for SKINVIVE by JUVÉDERM for Neck — First Indication Expansion
AbbVie's newest HA filler indication targets the décolletage and neck, a high-volume treatment area with limited approved options.
Injectables
AbbVie Wins FDA Approval for SKINVIVE by JUVÉDERM for Neck — First Filler Indication in Category
Allergan Aesthetics' new neck-appearance indication expands the JUVÉDERM filler portfolio beyond face and lips.
Injectables
FDA Approves Restylane Contour for Temple Hollowing — Galderma Expands Filler Indication Portfolio
Galderma gains clearance for HA filler in temple region, adding a new anatomical indication to its Restylane platform.
Injectables
FDA Approves Skinvive by Juvéderm for Neck Appearance — AbbVie Expands Filler Portfolio Beyond Face
Allergan Aesthetics gains clearance for injectable to improve neck lines and skin quality, opening a new revenue line for practices.
Injectables
Galderma Wins FDA Approval for Restylane Contour — Temple Indication Expands Structural Filler Segment
New indication for temple volume restoration adds a high-skill, high-margin treatment to Restylane's portfolio.
Injectables
Allergan Aesthetics Wins FDA Approval for Skinvive by Juvéderm — Neck Indication Expands Filler Portfolio
AbbVie's newest Juvéderm indication targets neck laxity and wrinkles, adding a high-margin treatment to the injectable mix.
Injectables
AbbVie Wins FDA Approval for Skinvive by Juvéderm — Neck Indication Expands Filler Portfolio
Allergan Aesthetics' newest indication targets a high-margin, underserved anatomical zone.
Injectables
Galderma Wins FDA Approval for Restylane Contour — Temple Hollowing Indication Expands Filler Anatomy
New labeled indication targets facial structure correction and premium pricing opportunity.
Injectables
Galderma Wins FDA Clearance for Restylane Contour — Temple Hollowing Now Indicated
Galderma's new temple indication for Restylane Contour directly competes with Allergan's Voluma and RHA for facial architecture.
Injectables
Restylane Contour Approved for Temple Hollowing — Galderma Fills a Clinical Gap
Galderma's new indication for Restylane Contour addresses a high-demand aesthetic concern and tightens competition in the volumization space.
Injectables
RHA Dynamic Volume Cleared for Midface Augmentation — Revance Expands Dynamic Filler Footprint
Revance's dynamic HA platform gains a new indication for age-related volume loss, positioning RHA as a competitor in the structural filler space.
Injectables
FDA Approves Skinvive by Juvéderm for Neck Lines — New Indication Expands Allergan's Dermal Filler Portfolio
Allergan Aesthetics wins clearance for Skinvive in neck appearance improvement, adding a second indication to its HA-based injectable platform.
Injectables
Galderma's Restylane Contour Cleared for Temple Hollowing — New Indication, Familiar Filler
Galderma expands Restylane's approved uses; temple augmentation becomes a mainstream injectable procedure.
Injectables
Skinvive by Juvéderm Wins FDA Approval for Neck — What's in Your Filler Mix Now
AbbVie's newest indication expands the Juvéderm franchise into a high-complaint zone; implications for your injectable protocol and patient conversation.
Injectables
Supply-Disruption Early Warning: Reading 483s and Recalls to Stock Ahead of a Shortage
Shortages don't appear overnight — they're preceded by regulatory and quality signals most owners never see. Reading them turns a scramble for product into a calm, well-stocked advantage.
Injectables
FDA Clears RHA Dynamic Volume for Midface Augmentation — Revance's Dynamic Filler Gains Broader Indication
Revance's RHA line now covers midface volume loss; the approval expands the dynamic-filler category beyond facial lines.
Injectables
Galderma Wins FDA Clearance for Restylane Contour in Temple Hollowing — Narrower Indication, Broader Competitive Pressure
Galderma's latest Restylane indication targets temple volume loss; the approval underscores the race to own specific anatomical zones.
Injectables
FDA Approves Skinvive by Juvéderm for Neck Appearance — What the Indication Means for Your Juvéderm Mix
Allergan's newest indication expands the Juvéderm portfolio beyond facial volume; practices now have an FDA-cleared injectable specifically for neck lines and skin quality.
Injectables
How Hyaluronidase Dissolves Filler: Mechanism, Vascular Occlusion Protocol, and Practice Liability
Hyaluronidase breaks down hyaluronic acid filler by cleaving glycosidic bonds—and knowing when to deploy it, how to manage vascular compromise, and who bears liability is essential to practice protection.
Injectables
Botox Units Per Area: Standard Dosing and Practice Economics
Typical neuromodulator units by facial zone, how to price per-unit, and what drives your margin on toxin revenue.
Injectables
RHA vs Juvéderm: Resilient HA and Vycross Technology Compared for Aesthetic Practice
Two distinct HA architectures—RHA's resilient polymer and Juvéderm's Vycross crosslinking—deliver different clinical profiles and longevity in dynamic facial zones.
Injectables
Daxxify vs Jeuveau: Duration, Cost, and Clinical Positioning
How the extended-duration toxin and the budget neuromodulator stack up on longevity, per-treatment economics, and market positioning.
Injectables
Botox vs Xeomin: Which Neuromodulator to Stock and Offer Your Patients
Both are FDA-approved botulinum toxin Type A products, but their formulations, onset profiles, dosing economics, and patient candidacy differ in ways that matter to your bottom line and clinical outcomes.
Injectables
What Is a Liquid Facelift? Filler and Toxin Combination Strategy for Medspa Owners
A liquid facelift pairs neuromodulators and dermal fillers to restore volume and smooth dynamic lines—here's how to structure, price, and present it to patients.
Injectables
What Is a Skin Booster? Category, Players, FDA Status, and Menu Strategy
Skin boosters are injectable hydration and biostimulation treatments positioned between skincare and fillers—with distinct regulatory pathways and revenue models for medspa operators.
Injectables
Skinvive by Juvéderm: The Microdroplet HA Skin Booster for Cheek Hydration
Skinvive is a microdroplet hyaluronic acid injectable designed to hydrate and smooth cheek skin—a new category between traditional fillers and topical skincare.
Injectables
What Is Rejuran? The Polynucleotide Skin Booster Reshaping the Aesthetic Market
Rejuran is a Korean-origin polynucleotide (PN) injectable that stimulates collagen and improves skin quality—but US availability remains limited despite growing practitioner and patient demand.
Injectables
Letybo vs. Botox: Key Differences in Units, Onset, and Clinical Profile for Medspa Owners
Letybo and Botox are not interchangeable: they differ in potency, diffusion, onset speed, and market positioning—here's what owners need to know about unit equivalency and patient outcomes.
Injectables
Is Relfydess FDA Approved? Status, Mechanism, and How It Compares to Dysport
Galderma's ready-to-use liquid botulinum toxin Type A received FDA approval in April 2024. Here's what medspa owners need to know about its formulation, clinical profile, and competitive positioning versus Dysport.
Injectables
Is Evolysse FDA Approved? Evolus's HA Filler Line Explained
Evolysse is FDA-approved and represents Evolus's entry into the hyaluronic acid filler market—here's how it compares to Juvéderm and Restylane.
Injectables
Sculptra vs Radiesse: Mechanism, Timeline, and Clinical Use Cases for Medspa Owners
Two FDA-cleared biostimulators with distinct mechanisms and patient outcomes—how to choose between PLLA and CaHA for your practice.
Injectables
Juvéderm vs Restylane: HA Filler Families Compared by Crosslinking, Indication, and Longevity
Both HA platforms dominate the market, but their crosslinking chemistry, rheology, and clinical performance differ—here's what drives your choice and your margin.
Injectables
Daxxify vs Botox: Duration, Cost, and When to Use Each
Daxxify's 6-month duration commands a premium, but Botox's 3-month cycle and lower cost make it the right choice for many practices and patients.
Injectables
Botox vs Jeuveau: Which Neuromodulator to Stock and Offer
Botox dominates market share and rebate programs, but Jeuveau offers competitive unit pricing and differentiation. Here's how to choose for your practice.
Injectables
Botox vs Dysport: Clinical Differences, Dosing, and Economics for Injectors
How onset, diffusion, unit conversion, and cost structure differ between the two leading neuromodulators, and when to stock each.
Injectables
Is Kybella FDA Approved? Current Status and What Medspa Owners Need to Know
Kybella holds full FDA clearance for submental fat reduction—here's the approval pathway, clinical evidence, and practice economics.
Injectables
Is Sculptra FDA Approved? Status, Indications, and Clinical Use
Sculptra holds FDA clearance for specific facial indications and is the market-leading PLLA biostimulator—but approval scope matters for your practice.
Injectables
Are RHA Fillers FDA Approved? Current Status and Clinical Use
RHA fillers hold full FDA approval for dynamic wrinkles and folds, with three products cleared under 510(k) pathways and distinct rheological profiles suited to movement-rich zones.
Injectables
Is Xeomin FDA Approved? Status, Indications, and Clinical Profile
Xeomin holds full FDA approval for dynamic wrinkles and is the only "naked" botulinum toxin formulation on the U.S. market—here's what that means for your practice.
Injectables
Is Skinvive by Juvéderm FDA Approved? Status, Indications, and Microdroplet Technology
Skinvive received FDA clearance in 2023 for cheek and neck skin quality: here's what the approval covers and how the microdroplet formulation works.
Injectables
Is Letybo FDA Approved? Status, Mechanism, and Clinical Position
Letybo (letyrosine) received FDA approval in 2023 as a novel neuromodulator alternative to botulinum toxin for dynamic wrinkles—here's what medspa owners need to know about its regulatory path, mechanism, and market positioning.
Injectables
Is Jeuveau FDA Approved? Current Status and Clinical Indications
Jeuveau holds full FDA approval for glabellar lines and is positioned as a faster-acting neuromodulator alternative to Botox and Dysport.
Injectables
Is Daxxify FDA Approved? Status, Indications, and How It Compares to Botox
Daxxify received FDA approval in September 2023 as a long-acting neuromodulator with a different formulation and duration profile than Botox.
Injectables
Allergan Aesthetics Wins FDA Approval for Skinvive by Juvéderm — Neck Wrinkles Now Cleared
AbbVie's newest Juvéderm indication expands the filler portfolio into a high-volume treatment zone.
Injectables
Allergan Aesthetics Wins Health Canada Approval for Boey — Rapid-Onset Neuromodulator Clears Regulatory Hurdle
AbbVie's next-generation toxin candidate gains approval in Canada; U.S. pathway remains unclear.
Injectables
RHA Dynamic Volume Wins FDA Clearance for Midface Augmentation — New Rheology Profile Enters Market
Revance's dynamic filler gains approval for midface volume loss, offering an alternative to crosslinked HA.
Injectables
Biostimulator Supremacy: Why Sculptra-Class Products Are Eating Filler's Lunch
The injectable conversation is shifting from instant volume to collagen built over time — and the practices that adapt their consult, pricing, and inventory to the biostimulator era will own the higher-value patient.
Injectables
Manufacturer Contract Season: How to Negotiate Volume Tiers Before You Re-Sign
The contract you re-sign on autopilot is the one that costs you all year. Treating contract season as a deliberate negotiation — armed with your real volume and credible alternatives — is among the highest-ROI hours an owner spends.
Injectables
Building a Tox-and-Filler Loyalty Stack: Layering Allē, Aspire, and Evolus Rewards Without Cannibalizing Margin
Manufacturer loyalty programs are patient-acquisition tools you didn't build and don't pay for — until you let them quietly dictate what you stock and train your patients to chase points instead of results.
Injectables
Anticipating the Next Injectable Price Increase: The Signals That Precede a List-Price Hike
Manufacturer price increases aren't random — they follow patterns and leave footprints. Reading the signals lets you stock ahead, lock contracts, and protect margin before the new number lands.
Injectables
Hyaluronidase Protocols: Stocking, Dosing, and the Vascular-Occlusion Emergency Kit Every Room Needs
The cost of stocking hyaluronidase and building an occlusion protocol is trivial. The cost of not having it when a filler patient blanches is a necrosis, a lawsuit, and the end of a reputation.
Injectables
Filler Rheology for Owners: G-Prime, Cohesivity, and Why It Dictates Which Product for Which Plane
You don't have to inject to run a profitable filler menu, but you do have to understand why a high-G-prime product belongs deep on bone and a soft, cohesive one belongs in the lip. It drives your inventory, your pricing, and your complication rate.
Injectables
Switching Your Tox: The Operational Playbook for Inventory, Retraining, Patient Comms, and the Rebate Reset
Changing your primary neurotoxin looks like a purchasing decision. It's actually an operations project — and the practices that botch it lose patients and rebate standing in the same quarter.
Injectables
Cannula vs Needle Economics and Liability: When the Safer Technique Is Also the Better Margin
The cannula-versus-needle debate is usually framed as pure clinical preference. For an owner, it's also a question of consumable cost, treatment time, and where your liability exposure actually sits.
Injectables
Managing Tox Resistance and Neutralizing Antibodies: Counseling the Patient and Switching Formulations
When a reliable patient suddenly 'stops responding' to their neurotoxin, the conversation that follows tests your clinical credibility and your retention. Here's how to handle resistance without losing the patient.
Injectables
The Real Cost-Per-Unit Breakdown: Botox vs Dysport vs Jeuveau vs Daxxify vs Letybo (Loaded, Not List)
List price is a decoy. The number that decides which toxin actually makes you money is loaded cost per *clinically equivalent* unit, after rebates, dosing conversion, and duration.
Injectables
Dysport-to-Botox Conversion Ratios in Practice: Pricing and Dosing When You Run Both
The 2.5:1 ratio is the textbook answer. Running both products profitably means knowing where that ratio bends, how to price so patients can't arbitrage you, and how to keep injectors consistent.
Injectables
Kybella vs CoolSculpting for the Double Chin: Injectable vs Device for Submental Fat
Two very different approaches to the same popular concern. The comparison patients want covers mechanism, sessions, and which fits their situation.
Injectables
Reconstitution & Dilution Economics: How Your Saline Volume Quietly Changes Your Cost-Per-Unit
Dilution is a clinical decision with a financial tail. The vial holds 100 units no matter what — the question is how many you actually bill before the rest hits the sharps container.
Injectables
How Long Does Botox Take to Work — and Why the Answer Is a Retention Tool
The onset question patients ask is an expectation-setting opportunity. Practices that answer it well prevent the 'it didn't work' panic and the unnecessary early follow-up.
Injectables
Overfill Math: Getting 22–25 Units Out of a '20-Unit' Vial Without Compromising Results
Manufacturers slightly overfill vials. Whether that surplus becomes billed revenue or sharps-container waste is a function of your draw technique and your tracking — not luck.
Injectables
Jawline Definition: The Treatment Options and the Consult That Sells the Plan
Jawline is one of the fastest-growing requests, especially among men. The strongest results — and revenue — come from a plan, not a single treatment, and a consult built to present it.
Injectables
PRF vs Filler for the Under-Eye: Two Approaches to a Delicate Area
The under-eye is a high-stakes area where the choice between approaches must be especially careful and patient-specific.
Injectables
Diffusion Profiles That Matter Chairside: Why Field-of-Effect Changes Your Injection Map by Product
Diffusion isn't an academic property — it changes where you place product, how many points you use, and your complication risk. An owner who understands it builds better protocols and reads outcomes more accurately.
Injectables
Restylane vs RHA: How Owners Should Think About Two HA Filler Families
Both are hyaluronic acid filler families with multiple products. The comparison patients and owners want is really about matching products within each line to the job.
Injectables
Radiesse vs Hyaluronic Acid Filler: Biostimulator-Type vs HA Volume
They're different categories of injectable working differently — one stimulating, one HA-based — which affects selection, reversibility considerations, and positioning.
Injectables
Treating Under-Eye Concerns: Matching the Approach to the Cause (an Owner's Overview)
Under-eye complaints are among the most-requested and most-nuanced. The right approach depends on the actual cause — and mismatching it is a fast route to a hard-to-fix disappointment.
Injectables
Dysport vs Daxxify: Diffusion and Duration as the Two Axes That Matter
These two neurotoxins are often weighed against each other on the dimensions patients and injectors actually care about: how they spread and how long they last.
Injectables
'Baby Botox' vs Traditional Dosing: Subtlety as a Treatment Philosophy
Same product, different philosophy. 'Baby Botox' is about lighter, more natural results — a trend worth understanding for consults and positioning.
Injectables
How Long Does Dysport Last — and Using Onset and Duration to Set Expectations
Patients comparing neurotoxins ask about onset and duration. Answering accurately sets expectations and supports rebooking cadence — and prevents the 'mine wore off fast' complaint.
Injectables
Thread Lift vs Filler: Lift vs Volume, and Setting the Right Patient Expectation
Patients conflate them; they do different things. Filler restores volume, threads provide a lifting effect — and the wrong expectation is the fastest route to a disappointed patient.
Injectables
Filler vs Fat Transfer: Injectable Volume vs a Surgical Approach
Both restore volume, but one is an in-office injectable and the other a surgical procedure — a distinction that shapes who offers it and what patients are choosing between.
Injectables
How Long Does Lip Filler Last — and How Owners Should Use That for Rebooking Cadence
The 'how long does it last' question patients ask is also a rebooking-cadence question owners should answer deliberately. Tie the clinical reality to your retention system.
Injectables
Lip Flip vs Lip Filler: Two Different Treatments Patients Constantly Confuse
Same area, different treatments, very different results. The confusion between them is a leading cause of disappointed lip patients.
Injectables
How Much Does Sculptra Cost — and How Owners Should Price the Biostimulator Series
Sculptra isn't priced like filler, and pricing it like filler is how practices lose money on it. The series-and-results model demands a different pricing logic.
Injectables
Semaglutide vs Tirzepatide for Medspas: What Owners Need to Know About Offering Each
The two GLP-1-class names driving your weight-management demand differ clinically and commercially. Here's the owner's-eye comparison of offering each.
Injectables
How Much Does Lip Filler Cost — and How Owners Should Frame Lip Pricing
Lip filler is one of the most-searched price questions in aesthetics. How you frame the price shapes conversion as much as the number.
Injectables
Dysport vs Jeuveau: Two Neurotoxin Alternatives in Different Lanes
Both compete with Botox, but on different terms — diffusion profile versus value positioning. The owner's comparison is about fit and cost, not a clinical leaderboard.
Injectables
Botox vs Fillers: When Each Is the Right Tool (and Why Patients Confuse Them)
The most common injectable confusion in the building — they do opposite things. Here's the clear distinction that anchors every good injectable consult.
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.